NASDAQ: PFSA
Profusa Inc Earnings Dates, Reports, Calls

Profusa earnings were -$11.1M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest PFSA earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$2.7M, down 66.5% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, PFSA reported annual earnings of -$9.2M, with -10.2% growth.

PFSA earnings history

Current Revenue
$100.0k
Current Earnings
-$11.1M
Current Profit Margin
-11,125.7%

PFSA Return on Equity

Current Company
N/A
Current Industry
7.5%
Current Market
31.3%

PFSA undefined

Current Company
-187.9%
Current Industry
8.7%
PFSA is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when PFSA announces earnings.

PFSA undefined

Current Company
9.68%
Current Industry
9.1%
PFSA has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

PFSA vs Medical Device Stocks

TickerEBITDAEarningsY/Y EarningsEPS
PFSA-$5.49M-$11.13MN/A-$1.99
IRIX-$5.69M-$7.13MN/A-$0.43
NSYS-$1.36M-$3.38MN/A-$1.23
ADGM-$64.71M-$67.94MN/A-$12.16
VVOS-$10.63M-$11.24MN/A-$1.73

Profusa Earnings Reports & History FAQ

What were Profusa's earnings last quarter?

Profusa (NASDAQ: PFSA) reported Q1 2025 earnings per share (EPS) of -$0.48, up 11.63% year over year. Total PFSA earnings for the quarter were -$2.72 million. In the same quarter last year, Profusa's earnings per share (EPS) was -$0.43.

If you're new to stock investing, here's how to buy Profusa stock.

Is Profusa profitable or losing money?

As of the last Profusa earnings report, Profusa is currently losing money. Profusa's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$11.13 million, a 15.12% decrease year over year.

What was PFSA's earnings growth in the past year?

As of Profusa's earnings date in Q3 2025, Profusa's earnings has grown year over year. PFSA earnings in the past year totalled -$11.13 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.